News & Industry Bulletins

Tuesday, January 16, 2018

‘You’re doing the right thing’: Addiction experts applaud Utah for homeless reform

A pair of nationally recognized leaders for addiction treatment praised Utah for Operation Rio Grande on Thursday — while also urging state officials not to give in to community pushback that inevitably comes with efforts to address homeless issues.

Wednesday, January 10, 2018

Utah Speaker Greg Hughes to host pre-legislative conversation on homelessness, substance abuse and mental health

Speaker Greg Hughes will host a conversation on homelessness, substance abuse and mental health with leading experts in the field. Participants will include Dominion Diagnostics Scientific Advisory Board Member David E. Smith, MD and Mary P. Hauser, MA, Vice President of Addiction Services and New Market Development for Dominion Diagnostics.

Tuesday, January 9, 2018

The Institute for the Advancement of Behavioral Healthcare and Dominion Diagnostics Announce Extended Partnership in Addiction Treatment Education

Today, the Institute for the Advancement of Behavioral Healthcare and Dominion Diagnostics announce they will continue their long-standing partnership over the next two years to support education for addiction treatment professionals facing the substance abuse and addiction crisis.

Wednesday, November 29, 2017

Industry Leader Dominion Diagnostics Celebrates 20 Years

In 2017, Dominion Diagnostics, LLC celebrated two decades as one of the country's leading drug monitoring companies.  Delivering the highest level of commitment to compliance, quality, innovative technology and tools, clinically relevant education and customer support has led them to be a premier choice in laboratory testing for the addiction treatment, behavioral health, and pain management fields.

Monday, July 24, 2017

'Grey death': The powerful street drug that's puzzling authorities

A new drug called "grey death" has been linked to a handful of lethal overdoses in the South -- but no one knows exactly what's in it or where it's coming from. The drug, a mix of opioids, can kill in very small doses and looks like concrete mixing powder.

Wednesday, June 21, 2017

Dominion Diagnostics Honored As One of the 2017 Best Places to Work in Rhode Island

Dominion Diagnostics has been named as one of the 2017 Best Places to Work in Rhode Island. First recognized two years ago among the 2015 Best Places to Work in Rhode Island winners, this marks Dominion's second honor in the annual list.

Thursday, March 16, 2017

American cocaine use is on the rise

The number of cocaine overdose deaths in 2015 was the highest since 2006 and the number of young Americans trying the drug for the first time increased 61 percent from 2013 to 2015. This increase in use appears to be related to Columbia’s growing coca plant harvest, which doubled between 2013-2015. Test samples of cocaine seized from the streets in the US found that 90 percent were of Colombian origin.

Wednesday, March 1, 2017

Common Misperceptions about Alcohol Metabolites: Ethyl Glucuronide and Ethyl Sulfate

Ethyl glucuronide and ethyl sulfate (EtG and EtS) are minor metabolites of ethanol (alcohol) that can be used to help identify recent ethanol exposure, even after ethanol is no longer measurable. Discussions on the interpretation of EtG and EtS urine test results frequently arise in programs utilizing these tests. Concerns have mostly centered around windows of detection and the sources of the ethanol metabolites when monitoring abstinence (i.e. non-beverage versus beverage).

Monday, January 9, 2017

Opioid Epidemic Fuels Increase in Cocaine Related Overdose Deaths

According to a recent U.S. News & World Report article, the number of people dying from cocaine related overdoses is growing.  This seems to be due to the fact that they are mixing cocaine with opioids such as heroin and fentanyl.  The article states that it is not known whether people are mixing the drugs intentionally or are taking products that are tainted. 

Tuesday, October 11, 2016

DEA Delays Kratom Ban

The US Drug Enforcement Administration (DEA) has not taken action to make the herbal supplement kratom as schedule I drug, despite previously announcing its intention to do so by September 30. The delay comes as some members of Congress, as well as kratom users and researchers, have grown increasingly vociferous over the notion that the DEA would make kratom a schedule I substance, in the same class as heroin and marijuana, without allowing any public input.